OKYO Pharma Limited (OKYO) Stock Analysis

What OKYO Pharma Limited does

OKYO Pharma Limited is a biopharmaceutical firm operating at the preclinical stage, dedicated to developing innovative treatments for individuals in the United Kingdom experiencing inflammatory eye conditions and ocular discomfort. Its primary therapeutic candidate is OK-101, specifically designed to address dry eye disease. Additionally, the company is advancing OK-201, an experimental bovine adrenal medulla lipidated-peptide analogue, intended to treat neuropathic ocular pain. Established in 2007, OKYO Pharma Limited maintains its headquarters in London, UK.

Key metrics

ETFs linked to OKYO

Broad-market and Healthcare sector ETFs an investor holding OKYO Pharma Limited is often also exposed to. Open an ETF page to see its actual top holdings.

PortView Portfolio Insights

PortView analyzes how OKYO fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.

Similar companies

Frequently asked questions

What is the ticker symbol for OKYO Pharma Limited?

OKYO Pharma Limited trades under the ticker OKYO on NASDAQ.

Which exchange is OKYO listed on?

OKYO is listed on NASDAQ.

What sector does OKYO Pharma Limited operate in?

OKYO Pharma Limited is classified in the Healthcare sector (Biotechnology industry).

How can PortView help analyze OKYO in a portfolio?

PortView shows OKYO's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.